Table 1 Comparison responders - non responders
From: Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer
Responders | Non responders | ||
|---|---|---|---|
Variables | (n = 269) | (n = 29) | P-value |
Age (year) | 66,4 ± 7,2 | 65,6 ± 7,9 | 0,67 |
Pre-treatment index of prostatic symptom score (IPSS) | 4,1 ± 2,8 | 4,2 ± 2,8 | 0,75 |
Pre-treatment PSA (ng/ml) | 6,7 ± 2,3 | 7,1 ± 2,4 | 0,32 |
Pre-treatment prostate volume (cm3) | 34,2 ± 9,7 | 33,7 ± 9,6 | 0,89 |
Gleason score (% points) | 0,52 | ||
< VII | 82 | 79 | |
VII | 18 | 21 | |
Clinical tumour stage (% points) | 0,43 | ||
T1C | 60 | 72 | |
T2 | 40 | 28 | |
Neoadjuvant hormonal therapy (% points) | 27,5 | 38 | 0,28 |
Follow-up (year) | 3,0 ± 1,5 | 2,6 ± 1,3 | 0,24 |
D90 (minimal dose received by 90% of the prostate gland) | 159,8 ± 21,8 | 151,7 ± 21,7 | 0,08 |
U30* (minimal dose received by 30% of urethra) | 215,5 ± 44,0 | 198,5 ± 40,0 | 0,06 |
V100* (percentage of the prostate volume receiving 100% of the prescribed dose) | 87,7 ± 8,0 | 85,5 ± 7,6 | 0,09 |
V150* (percentage of the prostate volume receiving 150% of the prescribed dose.) | 47,5 ± 14,6 | 43,0 ± 12,0 | 0,14 |
RV160* (surface of rectum receiving 160 Gy) | 0,58 ± 0,76 | 0,42 ± 0,55 | 0,42 |
Number of implanted seeds | 74,2 ± 11,7 | 72,1 ± 12,6 | 0,41 |
Number of implanted needles | 21,2 ± 2,7 | 21,3 ± 3,0 | 0,87 |